Key features and details | |
Cat. No. | MABL-1627 |
Name | Anti-FSH receptor mAbs |
Clone No. | AFD- 9H11 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | therapeutic, ELISA, FC, IF |
Species Reactivity | Human, Mouse |
Basic Information | |
Specificity | This antibody binds human and mice FSH receptor. FSH receptor is a G protein-coupled receptor for follitropin, the follicle-stimulating hormone. Through cAMP production activates the downstream PI3K-AKT and ERK1/ERK2 signaling pathways. |
Alternative Name | FSHR; FSH-R; Follicle-stimulating hormone receptor; Follitropin receptor; LGR1 |
UniProt | P23945 |
Immunogen | The original antibody was generated by immunizing Balb/c mice with an optimized DNA construct encoding human FS R |
Application Notes | To test if the antibody dependent cellular cytotoxicity elicited by the mouse version of this antibody translated into an in vivo anti-tumor effect, mice were challenged with IDS -Defl29/Vegf-a-Fshr and treated with the mouse version of this antibody. The antibody was able to delay tumor progression. To further characterize the antibody its ability to bind cells expressing human and mouse FHSR, flow cytometry was performed using the mouse version of this antibody on A20 cells, ID8- Defl29/Vegf-a-Fshr cells and human ovarian cancer cell lines like Caov3, OVCAR3, TOV21 G and PC3 with physiological levels of FSHR. Isotype analysis of the antibody was done using ELISA. Finally immunofluorescence was performed on 293T cells transduced with human or murine FSHR using the mouse version of this antibody (WO2020033797). |
Antibody First Published | Perales-Puchalt et al. WO2020033797 |
Note on publication | |
COA Information (For reference only, actual COA shall prevail) | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |